OTLK Stock Surges Over 50% Pre-Market, Breaches Key Technical Milestone – What’s Behind This Massive Rally?

• The FDA concluded that the company had provided sufficient evidence supporting the treatment’s effectiveness for wet AMD.
• The treatment has already been approved in the European Union and the United Kingdom.
• OTLK shares breached their 100-DMA for the first time in nearly 5 months.

Shares of Outlook Therapeutics, Inc. (OTLK) skyrocketed more than 50% in premarket trading on Tuesday, after the company scored a major FDA victory that reinforced confidence in the effectiveness of its eye disease therapy.

OTLK stock also breached its 100-day moving average (100-DMA) for the first time in nearly five months.

Source: TradingView

FDA’s Decision Leads To Rally In OTLK Stock

Outlook Therapeutics said the U.S. Food and Drug Administration (FDA) granted its appeal following a Formal Dispute Resolution (FDR) process related to its eye disease drug Lytenava. The FDA concluded that the company had provided sufficient evidence supporting the treatment’s effectiveness for neovascular age-related macular degeneration, also known as wet AMD.

Following the decision, Outlook Therapeutics said it plans to resubmit its Biologics License Application (BLA) for the treatment in June 2026. The company expects the filing to receive a Class 1 review, with a regulatory decision possible within 60 days after resubmission.

The company held an FDR meeting in April to discuss the regulatory pathway for its eye disease treatment. The meeting followed an FDA Type A meeting regarding the Complete Response Letter issued for the drug’s application for wet AMD.

Lytenava Has Already Been Approved In EU and UK

If approved, Lytenava could become the first FDA-approved ophthalmic formulation of Bevacizumab for retinal diseases. Bevacizumab is a targeted antibody that reduces the growth of new blood vessels.

The treatment has already been approved in the European Union and the United Kingdom for wet AMD. The drug works by blocking VEGF, a protein linked to abnormal blood vessel growth in the retina.

One user called it a “massive win.”

Another user expects the stock to potentially climb to $6.

The stock has shed around 83% so far this year.

Read also: LLY Stock Back In Spotlight After Sealing 10th Acquisition This Year – Expands Beyond Obesity With $3.8B Vaccine Bet

For updates and corrections, email newsroom[at]stocktwits[dot]com.